United States based pharmaceutical development company Aikido Pharma Inc. (AIKI) has received a sublicense for using psilocybin treatment of neuro-inflated tissue in patients suffering from cancer.
This sublicense is related to a technology linked to use of central nervous system (CNS) homing peptides to treat neuro-inflammatory disease in cancer patients. The homing peptides stated in the sublicense can help the delivery of therapeutic agents to inflamed CNS tissue.
Recent studies have shown that psychedelics such as psilocybin have anti-inflammatory activity in addition to their potential efficacy for the treatment of a wide range of neurological disorders.
Not long ago, while at Mount Sinai Center for Psychedelic Psychotherapy and Trauma Research, the company announced its support towards psilocybin research for post-traumatic stress disorder treatment.